Outcomes of Patients With Familial Central Precocious Puberty due to Mutations of <i>MKRN3</i> Gene After Treatment With Gonadotropin-Releasing Hormone Agonist.

ABSTRACT:

Objective

To assess the therapeutic effects of gonadotropin-releasing hormone agonist (GnRHa) on children with familial central precocious puberty (FCPP) due to Makorin ring finger Protein 3 (MKRN3) gene mutations.

Methods

Children with central precocious puberty (CPP) who were admitted to the Pediatric Endocrinology Department of Shanghai Ruijin Hospital from 2014 to 2021 were enrolled, of whom 4 FCPP children with MKRN3 gene mutations, including 3 girls and 1 boy, were selected as research subjects. Their height, weight, body mass index (BMI), predicted adult height (PAH), bone age, bone age advance (BAA, bone age minus chronological age), height-based standard deviation scores (Ht-SDS) corresponding to the chronological age, concentrations of sex hormones (luteiniz

SUBMITTER: Chen Z 

PROVIDER: S-EPMC12662689 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature